Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05566275 · ClinicalTrials.gov registry record
Remote Cognitive Assessment for Surgical Patients
A clinical trial of Mild Cognitive Impairment and Delirium, sponsored by University of California, San Francisco.
- Completed
- Registry status
- 34
- Enrollment target
- 1
- Study location
NCT05566275: Completed study of Mild Cognitive Impairment and Delirium, sponsored by University of California, San Francisco.
NCT05566275 is a study of Mild Cognitive Impairment and Delirium that has completed, run by University of California, San Francisco. The registered enrollment target is 34 participants, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05566275, a study of Mild Cognitive Impairment and Delirium, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot study to evaluate the use of remote cognitive testing to identify patients who may have cognitive vulnerability and may benefit from cognitive care pathways. Participants in this study are asked to complete a smartphone battery of thinking, memory, speech, and motor function tests on their smartphone.
Primary Outcome
Postoperative Delirium is measured by clinical assessment using the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU), or the Nursing Delirium Screen Scale (Nu-DESC). A composite delirium score is calculated, and patient is included in the delirium group if either CAM-ICU or NuDESC screenings are positive during the hospital stay. Electronic medical records will also be evaluated for any delirium diagnosis.
Conditions Studied
Study Locations (1)
California
- University of California San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2022-06-29 |
| Est. Completion | 2024-02-29 |
What the finished NCT05566275 record still lists
NCT05566275 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 0 interventions.
NCT05566275 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05566275 about?
NCT05566275 is a clinical study titled "Remote Cognitive Assessment for Surgical Patients". This is a pilot study to evaluate the use of remote cognitive testing to identify patients who may have cognitive vulnerability and may benefit from cognitive care pathways. Participants in this study are asked to complete a smartphone battery of thinking, memory, speech, and motor function tests on...
What is the current status of trial NCT05566275?
This trial is currently completed. The enrollment target is 34 participants. The study started on 2022-06-29. Estimated completion is 2024-02-29.
What conditions does trial NCT05566275 study?
This clinical trial studies the following conditions: Mild Cognitive Impairment, Delirium.
Who is sponsoring clinical trial NCT05566275?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05566275 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mild Cognitive Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05566275's enrollment target sits among peer trials
34 161st of 205 higher than 44 of 205 other Mild Cognitive Impairment trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mild Cognitive Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Wayfinding Intervention and Long-Term Memory
RECRUITING · NA
-
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
RECRUITING · Early Phase 1
-
MCI Speech in Noise
RECRUITING
-
Dual Task Perturbation Training for OAwMCI
RECRUITING · NA
-
Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY
RECRUITING
-
Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI